BAM
RLMD icon

Byrne Asset Management’s Relmada Therapeutics RLMD Stock Holding History

Byrne Asset Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$3 – 629
2022
Q4 		$3 Sell
1
-3,499
-100% -$30.7K ﹤0.01% 519
2022
Q3 		$130K Hold
3,500
– – 0.1% 137
2022
Q2 		$66K Sell
3,500
-3,175
-48% -$69.3K 0.05% 170
2022
Q1 		$180K Buy
6,675
+875
+15% +$18.1K 0.11% 116
2021
Q4 		$131K Buy
+5,800
New +$129K 0.08% 142

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Byrne Asset Management's RLMD Position: Q1 2023 in Review

Byrne Asset Management sold out of Relmada Therapeutics (RLMD) in Q1 2023, closing a stake of 1 share — an estimated $3 sold.

Byrne Asset Management first reported a position in RLMD in Q4 2021 and held it in 5 quarters. The position peaked at $180K in Q1 2022. 91 funds tracked by Wall St. Rank hold RLMD as of Q1 2023.

  • Byrne Asset Management reported no remaining Relmada Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Byrne Asset Management sold 1 Relmada Therapeutics share in Q1 2023, an estimated $3.
  • Byrne Asset Management first reported a position in Relmada Therapeutics in Q4 2021 and held it in 5 quarters.
  • Byrne Asset Management's Relmada Therapeutics position peaked at $180K in Q1 2022.
  • 91 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2023.

Based on Byrne Asset Management's 13F filing for Q1 2023, filed 17 Apr 2023.